1. Advances in Myeloid Malignancies

2. This program may include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Acute Myeloid Leukemia

4. Key Novel Agents for the Treatment of AML

5. Phase 1 Study of Vadastuximab Talirine (33A) in Older Pts With Treatment-Naive CD33-Positive AML

6. Phase 1 Study of Vadastuximab Talirine Plus Hypomethylating Agents in Older Patients With Treatment-Naive AML

7. Phase 1b Study of Vadastuximab Talirine Plus 7+3 Induction Therapy in Frontline AML

8. Phase 1 Study of Mutant IDH1 Inhibitor AG-120 in Pts With IDH1 Mutation-Positive Hematologic Malignancies

9. CHRYSALIS Phase 1/2 Study of Gilteritinib in Patients With R/R AML

10. Phase 1 Study of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Older Patients With AML

11. Phase 1 Dose-Escalation Study of MDM2 Inhibitor DS-3032b in Patients With Hematologic Malignancies

12. Phase 3 Trial of CPX-351 Vs 7 + 3 in Pts With Treatment-Naive Secondary AML: Subset Analyses

13. Summary of Key Investigational Agents in AML

14. Chronic Myeloid Leukemia

15. British DESTINY Study TKI Dose Reductions in Patients With Stable Molecular Responses

16. ENESTop Phase 2 Study Evaluating TFR in Patients With CP-CML Switching From Imatinib to Nilotinib

17. EURO-SKI Trial TKI Cessation in Patients With CML in Deep Molecular Response

18. CV Events in Patients Receiving TKIs

19. Effects of Comorbidities on TKI-Related QOL Changes in Patients With CP-CML

20. Phase 1 Study of BCR-ABL Inhibitor ABL001 in Patients With CP-CML and Prior TKI Failure

21. Phase 1 Study of Ruxolitinib Plus Nilotinib in Patients With CP-CML and Molecular Evidence of Disease

22. Conclusions: Recent Advances in CML

23. Myeloproliferative Neoplasms

24. PERSIST-2 -- Phase 3 Trial of Pacritinib Vs Best Available Therapy (Including Ruxolitinib) in Patients With MF and Thrombocytopenia Study Design

25. PERSIST-2 Results

26. PROUD-PV Phase 3 Trial of AOP2014 Vs HU in Patients With PV

27. MPD-RC 112 Phase 3 Trial of Frontline PegIFN Alfa 2a Vs HU in Patients With High-Risk PV and ET

28. Living With MPN Patient Survey Effects on Employment

29. International MPN LANDMARK Survey Effects of MPNs on QOL and Productivity

30. Myelodysplastic Syndrome

31. Phase 1 Study of Mutant IDH2 Inhibitor Enasidenib In Patients With MDS

32. PACE-MDS Phase 2 Study of Luspatercept in Patients With Low-Intermediate-Risk MDS

33. MDS Clinical Research Consortium Phase 2 Study of Low-Dose DEC Vs AZA in Patients With Low- or Intermediate-1-Risk MDS

34. E2905 Phase 3 Trial of Len Plus EA in Epo-Refractory Lower-Risk Non-Del(5q) MDS

35. Abbreviations

36. Abbreviations (cont)

37. Abbreviations (cont)

38. Abbreviations (cont)

39. Abbreviations (cont)

40. Abbreviations (cont)